Open an account

Avalo Therapeutics

AVTX · NASDAQ

$12.36+$0.77 (+6.64%)TodayMarket closed ·
Prev close $11.59

About AVTX

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. The company is headquartered in Wayne, Pennsylvania and currently employs 33 full-time employees. The company went IPO on 2015-11-13. The firm's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).

Employees
33
Headquarters
Wayne, Pennsylvania
Listed
Nov 13, 2015
Sector
Health Care
Industry
Biotechnology
Website
avalotx.com

AVTX key statistics

Market cap
662.87M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.09M
Volume
1.87M
Open price
$11.61
High today
$12.85
Low today
$11.26
52 Week high
$24.27
52 Week low
$11.21

Avalo Therapeutics (AVTX) at a glance

Avalo Therapeutics (AVTX) last traded at $12.36, with a market cap of 662.87M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $11.26 and $12.85. The current price is 9.8% above the day's low and 3.8% below its high.

Volume so far is 1.87M shares, above the average of 1.09M shares a day.

Over the past year Avalo Therapeutics has ranged from $11.21 to $24.27, and now sits 9% of the way up that range.

Avalo Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.83 per share against an estimate of -$0.5935.

The average analyst price target is $45.81, 270.6% above the current price, from 11 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 11 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 13 analystsAvg $45.81
Low
$30.30
Now
$12.36
High
$63.00

AVTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 14.1% on average.

  1. Q3 FY24: reported -$1.25 per share against an estimate of -$1.21
  2. Q4 FY24: reported -$7.95 per share against an estimate of -$0.3995
  3. Q1 FY25: reported -$1.25 per share against an estimate of -$1.41
  4. Q2 FY25: reported -$1.92 per share against an estimate of -$1.43
  5. Q3 FY25: reported -$2.19 per share against an estimate of -$1.69
  6. Q4 FY25: reported -$1.13 per share against an estimate of -$1.49
  7. Q1 FY26: reported -$0.98 per share against an estimate of -$1.05
  8. Q2 FY26: reported -$0.83 per share against an estimate of -$0.5935

AVTX news

  • Press releaseGlobe Newswire

    Avalo Therapeutics to Participate in Upcoming Investor Conferences

  • Press releaseGlobe Newswire

    Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

  • Evette Mitkov

    Avalo Therapeutics Stock Soars After Positive LOTUS Trial Results

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Market-Moving News for May 6th

  • Mohd Haider

    Avalo Therapeutics Stock Jumps 33% In Pre-Market Session: Here's Why

  • Press releaseGlobe Newswire

    Avalo Therapeutics to Participate in Upcoming Investor Conferences

Similar companies

Companies in the same industry as Avalo Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.